Your **Anktiva** treatment plan

Anktiva is a treatment that re-engages the immune system of patients with **BCG-unresponsive NMIBC** with **CIS** with or without papillary tumors.

Anktiva®
(nogapendekin alfa inbakicept-pmln)
400 mcg/0.4 mL, solution for intravesical instillation

Dosing and administration schedule

Use the space provided below to keep track of your treatment dates.

Induction* Anktiva + BCG 1x per week for 6 weeks

1 2 3 4 5 6 — No Treatment Weeks 12

Your treatment dates

Cystoscopy

Maintenance Anktiva + BCG 1x per week for 3 weeks every 3 months up to 1 year

1 2 3 — No Treatment Weeks 12

Your treatment dates

Cystoscopy

1 2 3 — No Treatment Weeks 12

Your treatment dates

Cystoscopy

1 2 3 — No Treatment Weeks 12

Your treatment dates

Cystoscopy

1 2 3 — No Treatment Weeks 12

Your treatment dates

Cystoscopy

For patients still in CR following the first year of maintenance therapy, patients should receive additional maintenance therapy with Anktiva + BCG 1x per week for 3 weeks every 6 months for an additional 2 years.

Patients are given a **cystoscopy** on the **12th week** of every treatment cycle to check if they have responded to treatment.

BCG, Bacillus Calmette-Guérin;
CIS, carcinoma in situ;
CR, complete response;
NMIBC, nonmuscle invasive bladder cancer.

*Patients who do not respond to the first induction cycle will be given another induction cycle. If they do not respond to the second induction cycle discontinuing Anktiva is recommended.

Please see Important Safety Information on back.

Anktiva®

(nogapendekin alfa inbakicept-pmln)
400 mcg/0.4 mL, solution for intravesical instillation

If you have questions, contact your healthcare provider or call **1-877-ANKTIVA** (1-877-265-8482).

What Should You Expect When Taking Anktiva?

During your treatment you should:

- Wear comfortable clothes. The treatment will last for at least 1 hour and you will need to hold the medicine in your bladder for two hours after it is administered.
- Avoid using the restroom until your treatment is done.
- Let your healthcare provider know if you have any cramping or feel like you urgently need to urinate.

After your treatment:

Some side effects may occur after taking Anktiva. The most common side effects include: fatigue, nausea, diarrhea, and changes in urination (such as discomfort, pain, burning, or red-colored urine).

- Red-colored urine may appear for the first 24 hours after treatment and could be a sign of blood in the urine.
- Report any changes in urination or prolonged red-colored urine to your healthcare provider.
- Be sure to drink water (stay hydrated) following treatment.

Call your doctor for medical advice about side effects if they continue for more than 2 days after treatment.

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION AND USAGE: ANKTIVA is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

WARNINGS AND PRECAUTIONS: Risk of Metastatic Bladder Cancer with Delayed Cystectomy. Delaying cystectomy can lead to the development of muscle invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after a second induction course of ANKTIVA with BCG, reconsider cystectomy.

DOSAGE AND ADMINISTRATION: For Intravesical Use Only. Do not administer by subcutaneous or intravenous routes. Instill intravesically only after dilution. Total time from vial puncture to the completion of the intravesical instillation should not exceed 2 hours.

USE IN SPECIFIC POPULATIONS: Pregnancy: May cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.

ADVERSE REACTIONS: The most common (≥15%) adverse reactions, including laboratory test abnormalities, are increased creatinine, dysuria, hematuria, urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills and pyrexia.

For more information about ANKTIVA, please see the full Prescribing Information at www.anktiva.com.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-1088. You may also contact ImmunityBio at 1-877-ANKTIVA (1-877-265-8482)

Reference: Anktiva (nogapendekin alfa inbakicept-pmln) prescribing information. ImmunityBio, 2024.

ImmunityBio®